Articles related to OBESITY/WEIGHT MANAGEMENT

New reports and studies are raising concerns about the gastrointestinal safety of semaglutide-containing medications; clinicians are advised to exercise caution and monitor patients for symptoms of gastroparesis.

This study offers valuable insights into the comparative efficacy and safety of apixaban and rivaroxaban in obese patients with NVAF, highlighting the need for a patient-centered approach in anticoagulant selection.

This pooled analysis provides robust evidence that low-dose glucocorticoids in RA treatment result in modest weight gain but do not elevate blood pressure. Consider these findings in your risk-benefit discussions with patients.

The updated prescribing guidelines for Wegovy (semaglutide) offer new maintenance dosing options for adults, reflecting recent research findings.

The recent systematic review comparing obesity management drugs highlights semaglutide and phentermine/topiramate as the most effective in weight loss and waist circumference reduction at 12 months. Explore the full study to understand the comparative efficacy and safety of these medications in obesity treatment.

The potential shortage of Saxenda (liraglutide) through 2023 underscores the importance of monitoring the availability of this weight management drug. Physicians should be aware of this situation and consider alternative options if necessary.